Drug Discovery & Development Magazine (09.11.2013)
Aids Weekly Plus
Certara, which provides software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, recently announced a partnership with the Critical Path Institute (C-Path) to develop a physiologically based pharmacokinetic model of the human lung. The model would work in combination with Certara’s Simcyp Population-Based Simulator to determine the disposition of drugs in the lungs and the potential impact of disease-progression on drug kinetics at different stages of TB infection. According to C-Path President and CEO Dr. Martha Brumfield, drug developers could use the model to define dose regimens that would produce clinical concentrations of drugs at specific sites in the lungs and help accelerate development of new TB drugs. The Critical Path to TB Drug Regimens Initiative supports this project.